Emerging safety issues regarding long-term usage of H₁-receptor antagonists

Bibliography

• NICHOLSON AN, PASCOE PA, STONE BM: Histaminergic systems and sleep-studies in man with H1 and H2 antagonists. Neuropharmacology (1985) 24:245–250.
   PubMed Web of Science ®Google Scholar
• SIMONS FER, SIMONS KJ: Pharmacokinetic optimisation of histamine Hl-receptor antagonist therapy. Clin. Pharmokin. Ther. (1991) 21:372–393.
   Google Scholar
• MELTZER EO: Comparative safety of H1 antihistamines. Ann. Allergy (1991) 67:625–633.
   PubMedGoogle Scholar
• SIMONS FER: Hl-receptor antagonists: comparative tolerability and safety. Drug Sal: (1994) 10:350–380.
   PubMed Web of Science ®Google Scholar
• WALSH GM: Second-generation antihistamines in asthma therapy - is there a protective effect? Am. j Resp. Med. (2002) 1:27–34.
   PubMedGoogle Scholar
• PASSALACQUA G, BOUSQUET J, BACHERT C et al.: The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy (1996) 51:666–675.
   Google Scholar
• LEURS R, SMIT MJ, TIMMERMAN H: Molecular pharmacological aspects of histamine receptors. Pharmacol. Ther. (1995) 66:413–463.
   PubMed Web of Science ®Google Scholar
• WALSH GM, ANNUNZIATO L, FROSSARD N et al.: New insights into the second generation antihistamines. Drugs (2001) 61:207–236.
   PubMed Web of Science ®Google Scholar
• VAN STEEKELENBURG J, CLEMENT PAR, BEEL MHL: Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests. Allergy (2002) 57:346–350.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates no clinically relevant differences between cetirizine, loratadine, ebastine, fexofenadine or mizolastine in the treatment of patients with allergic rhinitis.
   Google Scholar
• PARKINSON A, CLEMENT RE CASCIANO CN, CAYEN MN: Evaulation of loratadine as an inducer of liver microsomal cytochrome P450 in rat and mice. Biochem. Pharmacol (1992) 43:2169–2180.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, YOKOI T, KODAMA T, INOUE K, NAHASHIMA K, SHIMADA N: Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. Pharmacol Exp. Ther. (1998) 284:437–442.
   PubMed Web of Science ®Google Scholar
• HU YP, ROBERT J: Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. Biochem. Pharmacol (1995) 50:169–175.
   PubMed Web of Science ®Google Scholar
• RAMU A, RAMU N: Reversal of multidrugresistance by phenothiazines and structurally related compounds. Cancer Chemother. Pharmacol (1992) 30:165–173.
   PubMed Web of Science ®Google Scholar
• HAIT WN, GESMONDE JF, MURREN JR, YANG JM, CHEN HX, REISS M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. Pharmacol (1993) 45:401–406.
   PubMed Web of Science ®Google Scholar
• FISHER GA, LUM BL, HAUSDORFF J, SIKIC BI: Pharmacological considerations in the modulation of multidrug resistance. Eur. J Cancer (1996) 32:1082–1086.
   Google Scholar
• Data on file, UCB, SA, Brussels, Belgium.
   Google Scholar
• SALE ME, WOOSLEY RL, THAKKER K, PHILLIPS K, CARIDI F, CHUNG M: Effects of cetirizine and erythromycin, alone and in combination, on QT interval and pharmacokinetics in healthy subjects. Ann. Allergy Asthma bramurrol. (1996) 76:93.
   Google Scholar
• SALE ME, WOOSLEY R, THAKKER K, PHILLIPS K, CARIDI F, CHUNG M: A randomized, placebo-controlled, multiple-dose study to evaluate the electrocardiographic and pharmacokinetic interactions of azithromycin and cetirizine. Ann. Allergy Asthma Immurrol (1996) 76:93.
   Google Scholar
• VAN PEER A, CRABBE R, WOESTENBORGHS R, HEYKANTS J, JANSSENS M: Ketoconazole inhibits loratadine metabolism in man. Allergy (1993) 48\(Suppl. 16):34.
   Google Scholar
• GOOD AP, ROCKWOOD R, SCHAD P: Loratadine and ventricular tachycardia. Am. Cardiol (1994) 74:207.
   PubMed Web of Science ®Google Scholar
• BRANNAN MD, REIDENBERG P, RADWANSKI E et al.: Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin. Pharmacol Ther. (1995) 58:269–278.
   PubMed Web of Science ®Google Scholar
• SIMONS FER: Mizolastine: antihistaminic activity from preclinical data to clinical evaluation. Clin. Exp. Allergy (1999) 29:3–8.
   PubMed Web of Science ®Google Scholar
• SALMUN LM: Antihistamines in late-phaseclinical development for allergic disease. Expert Opin. Investig. Drugs (2002) 11:259–273.
   PubMed Web of Science ®Google Scholar
• •A comprehensive overview of new and emerging antihistamines.
   Google Scholar
• LEBRUN-VIGNES B, DIQUET B, CHOSIDOW 0: Clinical pharmacokintics of mizolastine. Clin. Pharmacolcinet. (2001) 40:501–507.
   Google Scholar
• KAY GG, HARRIS AG: Loratadine, a non-sedating antihistamine. Clin. Exp. Allergy (1999) 29:(Suppl. 3):147–50.
   Google Scholar
• ROSENZWEIG P, PATAT A: Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studies. Clin. Exp. Allergy (1999) 29\(Suppl. 3):156–162.
   Google Scholar
• HINDMARCH I, SHAMSI Z, STANLEY N, FAIRWEATHER DB: A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br .j Clin. Pharmacol (1999) 48:200–206.
   PubMed Web of Science ®Google Scholar
• •A recent and well-conducted study into the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function.
   Google Scholar
• NICHOLSON AN, STONE BM, TURNER C, MILLS SL: Antihistamines and aircrew: usefulness of fexofenadine. Aviat. Space Env-iron. Med. (2000) 71:2–6.
   PubMed Web of Science ®Google Scholar
• MARSHALL PS, COLON EA: Effects of the allergy season on mood and cognitive function. Ann. Allergy (1993) 71:251–258.
   PubMedGoogle Scholar
• SPAETH J, KLIMEK L, MOSGES R: Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy (1996) 51:893–906.
   PubMed Web of Science ®Google Scholar
• VUURMAN EF, VANVEGGEL LM, UITERWIJK MM, LEUTNER D, O'HANLON JF: Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy (1993) 71:121–126.
   PubMedGoogle Scholar
• MELTZER EIO, WELCH MJ: Adverse effects of Hl-receptor antagonists in the central nervous system. In: Histamine and Hi-receptor antagonists in allergic disease. Clinical Allergy & Immunology Series. Simons FER (Ed.), Marcel Dekker, Inc., New York, (1996)357–381.
   Google Scholar
• DUBUSKE L: Dose-ranging comparative evaluation of cetirizine in patients with seasonal allergic rhinitis. Ann. Allergy (1995) 74:345–354.
   Google Scholar
• HINDMARCH I, BHATTI JZ: The effects of terfenadine with or without alcohol on an aspect of driving performance. Clin. Exp. Allergy (1989) 19:609–611.
   PubMed Web of Science ®Google Scholar
• ROTH T, ROEHRS T, KOSHOREK G, SICKLESTEEL J, ZORICK F: Sedative effects of antihistamines. I Allergy Clin. Immunol (1987) 80:94–98.
   PubMed Web of Science ®Google Scholar
• VUURMAN EFPM, UITERWIJK MMC, ROSENZWEIG P, O'HANLON JF: Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur. I Clin. Pharmacol. (1994) 47:253–259.
   PubMed Web of Science ®Google Scholar
• KERR JS, DUNMORE C, HINDMARCH I: The psychomotor and cognitive effects of a new antihistamine, mizlolastine, compared to terfenadine, tripolidine and placebo in healthy volunteers. Eur. I Clin. Pharmacol. (1994) 47:331–335.
   PubMed Web of Science ®Google Scholar
• FALLIERS CJ, BRANDON ML, BUCHMAN E et al.: Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann. Allergy (1991) 66:257–262.
   PubMedGoogle Scholar
• HINDMARCH I, SHAMSI Z: Models to assess sedative properties of antihistamines. Clin. Exp. Allergy (1999) 29\(Suppl. 3):133–142.
   Google Scholar
• MATTILA MJ, PAAKKARI I: Variationsamong the non-sedating antihistamines: are there real differences? Eur. j Clin. Pharmacol. (1999) 55:85–93.
   Web of Science ®Google Scholar
• SIMONS FER: H1 receptor antagonists: safety issues. Ann. Allergy Asthma Immunot (1999) 83:481–488.
   PubMed Web of Science ®Google Scholar
• HORAK E STUBNER UP: Comparativetolerability of second generation antihistamines. Drug Sal: (1999) 20:385–401.
   PubMed Web of Science ®Google Scholar
• O'HANLON JF, RAMAEKERS JG: Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy (1995) 50:234–242.
   PubMed Web of Science ®Google Scholar
• CANONICA GW, HOLGATE ST, KARLSSON G et al.: The impact of allergic rhinitis on quality of life and other airway diseases. Allergy (1998) 53(Suppl.):1–31.
   Google Scholar
• SLATER JW, ZECHNICH AD, HAXBY DG: Second-generation antihistamines: a comparative review. Drugs (1999) 57:31–47.
   PubMed Web of Science ®Google Scholar
• LOCKEY RF, WIDILTZ MD, MITCHELL DQ et al: Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol (1996) 76:448–441.
   PubMed Web of Science ®Google Scholar
• HARVEY RE COMER C, SANDERS S et al.: Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. I Allergy Clin. Immunel (1996) 97:1233–1241.
   Google Scholar
• MANSMANN HC, ALTMAN LA, BERMAN BA et al.: Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann. Allergy (1992) 68:348–353.
   PubMedGoogle Scholar
• BERKOWITZ RB, DOCKHORN R, LOCKEY R et al.: Comparison of efficacy, safety and skin test inhibition of cetirizine and astemizole. Ann. Allergy Asthma Immunol (1996) 76:363–368.
   PubMed Web of Science ®Google Scholar
• CHAWEE WAN B, JAREONCHAI P, DHORRANINTRA B: A clinical comparison of cetirizine versus astemizole in perennial allergic rhinitis. Drug Investig. (1993) 5:222–228.
   Google Scholar
• BROIDE DH, LOVES, ALTMAN R, WASSERMAN SI: Evaluation of cetirizine in the treatment of patients with seasonal allergic rhinitis. I Allergy Clin. Immunot (1988) 81:176.
   Web of Science ®Google Scholar
• PANAYOTOPOULOS SM, PANAYOTOPOULOS ES: Efficacy of cetirizine in the treatment of seasonal allergic rhinoconjunctivitis. Ann. Allergy (1990) 65:146–148.
   PubMedGoogle Scholar
• RENTON R, FIDLER C, ROSENBERG R: Multicenter, crossover study of the efficacy and tolerability of terfenadine, 120 mg, versus cetirizine, 10 mg, in perennial allergic rhinitis. Ann. Allergy (1991) 67:416–420.
   PubMedGoogle Scholar
• KAISER HB: Hl-receptor antagonist treatment of seasonal allergic rhinitis. Allergy Clin. Immunol (1990) 86:1000–1003.
   Google Scholar
• BERMAN BA: Perennial allergic rhinitis: clinical efficacy of a new antihistamine. Allergy Clin. Immunol (1990) 86:1004–1008.
   Google Scholar
• BRAUNSTEIN G, MALAQUIN F, FAJAC I, MELAC M, FROSSARD N: Inhibition of histamine-induced nasal obstruction by cetirizine in allergic rhinitis. Br I Clin. Pharmacol. (1992) 33:445–448.
   PubMed Web of Science ®Google Scholar
• DAVIES BH: Prophylactic treatment of seasonal allergic rhinitis. Clin. Ther. (1991) 13:87–91.
   PubMed Web of Science ®Google Scholar
• KALIVAS J, BRENEMAN D, THARP M, BRUCE S, BIGBY M: Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. I Allergy Clin. Immunel (1990) 86:1014–1018.
   PubMed Web of Science ®Google Scholar
• KINT A, CONSTANDT L, ARENDT C, BERHEIM J: Comparative efficacy of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria. Acta Ther. (1989) 15:65–75.
   Google Scholar
• KIETZMANN H, MACHER E, RIHOUX J-P, GHYS L: Comparison of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria. Ann. Allergy (1990) 65:498–500.
   PubMedGoogle Scholar
• ANDRI L, SENNA GE, BETTELI C, GIVANNI S, ANDRI G: A comparison of the efficacy of cetirizine and terfenadine. A double-blind controlled study of chronic idiopathic urticaria. Allergy (1993) 48:358–365.
   Google Scholar
• GOH CL, WONG WK, LIM J: Cetirizineversus placebo in chronic idiopathic urticaria - a double blind randomised cross-over study. Ann. Acad. Med. Singapore (1991) 20:328–330.
   PubMedGoogle Scholar
• ALOMAR A, DE LA CUADRA J, FERNANDEZ J: Cetirizine versus astemizole in the treatment of chronic idiopathic urticaria. I Int. Med. Res. (1990) 18:358–365.
   PubMed Web of Science ®Google Scholar
• BURTIN B, FAYOL C, MARQUIS P, VALENTIN B, BOUSQUET J: Cetirizine improves quality of life as assessed by the SF-36 questionnaire (SF-36) in perennial allergic rhinitis. I Allergy Clin. Immunol (1994) 93:163.
   PubMed Web of Science ®Google Scholar
• BOUSQUET J, DUCHATEAU J, PIGNAT JC et al.: Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J. Allergy Clin. Immunel (1996) 98:309–316.
   PubMed Web of Science ®Google Scholar
• WATSON WT, SIMONS KJ, CHEN XY, SIMONS FER: Cetirizine: a pharmacokinetic and pharmacodynamic evaluation in children with seasonal allergic rhinitis. J. Allergy Clin. Immunel (1989) 84:457–464.
   PubMed Web of Science ®Google Scholar
• MAST M, CANDIANI R, VAN DE VENNE H: A placebo-controlled trial of cetirizine in seasonal allergic rhino-conjunctivitis in children aged 6 to 12 years. Fed. Allergy Immunel (1993) 4\(Suppl. 4):47–52.
   Google Scholar
• CIPRANDI G, TOSCA M, RICCA V et al.:Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its anti-allergic activity. Clin. Exp. Allergy (1997) 27:1160–1166.
   PubMed Web of Science ®Google Scholar
• SIMONS FER: Prospective long-term safetyevaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J. Allergy Clin. Immunel (1999) 104:433–440.
   PubMed Web of Science ®Google Scholar
• RAMAEKERS JG, UITERWIJK MM, O'HANLON JF: Effects of loratadine and cetirizine on actual driving and psychometric test performance and EEG during driving. Eur. j Clin. Pharmacol (1992) 42:363–369.
   PubMed Web of Science ®Google Scholar
• NICHOLSON AN, TURNER C: Central effects of the H1 antihistamine cetirizine. Aviat. Space Environ. Med. (1998) 69:166–171.
   PubMed Web of Science ®Google Scholar
• SCHWEITZER PK, MUEHLBACH MJ, WALSH JK: Sleepiness and performance during 3 day administration of cetirizine or diphenhydramine. I Allergy Clin Immunel (1994) 94:716–724.
   PubMed Web of Science ®Google Scholar
• SEIDEL WF, COHEN S, BLIWISE NG: Cetirizine effects on objective measures of daytime sleepiness and performance. Ann. Allergy (1987) 59:58–62.
   PubMedGoogle Scholar
• SEIDEL WF, COHEN S, BLIWISE NG: Direct measurement of daytime sleepiness after administration of cetirizine and hydroxyzine with a standardised electroencephalographic assessment. J. Allergy Clin Immunel (1990) 86:1029–1033.
   PubMed Web of Science ®Google Scholar
• HINDMARCH I: Psychometric aspects of antihistamines. Allergy (1995) 50:48–54.
   PubMed Web of Science ®Google Scholar
• MANN RD, PEARCE GL, DUNN N, SHAKIR S: Sedation with non-sedating' antihistamines: four prescription-event monitoring studies in general practice. Br Med. J. (2000) 320:1184-1186. This study used prescription adverse event monitoring in a total of 43,363 patients and demonstrated low odds ratios of risk of sedation by loratadine, cetirizine, fexofenadine and acrivastine.
   Google Scholar
• HONIG P, BARANIUK JN: Adverse effectsof Hl-receptor antagonists in the cardiovascular system. In: Histamine and Hl-receptor antagonists in allergic disease. Simons FER (Ed.), Marcel Dekker, Inc. New York (1996):383–412.
   Google Scholar
• SIMONS FER, KESSELMAN MS, GIDDINS NG, PELECH AN, SIMONS KJ: Astemizole-induced torsade de pointes. Lancet (1988) 2:624.
   PubMed Web of Science ®Google Scholar
• DAVIES AJ, HARINDA V, MCEWAN A, GHOSE RR: Cardiotoxic effect with convulsions in terfenadine overdose. Br Med. J. (1989) 298:325.
   PubMed Web of Science ®Google Scholar
• WOOLSEY RL, CHEN Y, FREIMAN JP, GILLIS RA: Mechanisms of the cardiotoxic actions of terfenadine. JAMA (1993) 269:1532–1536.
   PubMed Web of Science ®Google Scholar
• WOOLSEY RL: Cardiac actions of antihistamines. Ann. Rev Pharmacol Toxicol (1996) 36:233–252.
   PubMed Web of Science ®Google Scholar
• SALATA JJ, JURKIEWICZ NK, WALLACE AA, STUPIENSKI GUINOSSO PJ, LYNCH JJ: Cardiac electrophysiological actions of the histamine Hl-receptor antagonists astemizole and terfenadine compared with chlopheniramine and pyrilamine. Circ. Res. (1995) 76:110–119.
   PubMed Web of Science ®Google Scholar
• RAMPE DE, WIBLE B, BROWN AM, DAGE RC: Effects of terfenadine and its metabolite on a delayed rectifier K+ channel from human heart. Mal Pharmacol (1993) 44:1240–1245.
   PubMed Web of Science ®Google Scholar
• DUBUSKE LM: Second generation antihistamines: the risk of ventricular arrhythmias. Clin. Ther. (1999) 21:281–295.
   PubMed Web of Science ®Google Scholar
• SALE ME, WOOLSEY RL, BARBY JT, YEH J, CHUNG M: Lack of electrocardiographic effects of cetirizine in healthy humans. J. Allergy Clin Immunel (1993) 91:258.
   Web of Science ®Google Scholar
• MASON J, REYNOLDS R, RAO N: The systemic safety of fexofenadine HC1. Exp. Allergy (1999) 29\(Suppl. 3):163–170.
   Google Scholar
• WOOD SG, JOHN BA, CHASSEAUD LF, YEH J, CHUNG M: The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann. Allergy (1987) 5:931–934.
   Google Scholar
• SPENCER CM, FAULDS D, PETERS DH: Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs (1993) 46:1055–1080.
   PubMed Web of Science ®Google Scholar
• MARKHAM A, WAGSTAFF AJ: Fexofenadine. Dugs (1998) 55:269–274.
   Google Scholar
• DELAUCHE-CAVALLIER MC, CHAUFOUR S, GUERAULT E, LACTOUX A, MURRIETA M, WAJMAN A: QT interval monitoring during clinical studies with mizolastine, a new antihistamine. Clin. Exp. Allergy (1999) 29\(Suppl. 3):206–211.
   Google Scholar
• AFFRIME MB, LORBER R, DANZIG M, CUSS F, BRANNAN MD: Three months evaluation of electrocardiac effects of loratadine in humans. Allergy (1993) 47\(Suppl. 16):29.
   Google Scholar
• SANDERS RL, DOCKHORN RJ, ALDERMAN JL, MCSORLEY PA, WENGER TL, FROSOLONO MF: Cardiac effect of acrivastine compared to terfenadine. I Allergy Clin Immunel (1992) 89:183.
   Web of Science ®Google Scholar
• HEY J, DEL PRADO M, EGAN RW, SHERWOOD J, KRUETNER W: Loratadine produces antihistaminic activity without adverse CNS, ECG or cardiovascular effects in guinea pigs. Comparative study with terfenadine and sedating antihistamines. Int. Arch. Allergy Immunel (1995) 107:418–419.
   Google Scholar
• HEY J, DEL PRADO M, SHERWOOD J, KRUETNER W, EGAN RW: Comparative analysis of the cardiotoxicity proclivites of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Armeimittelforschung (1996) 46:153–158.
   PubMed Web of Science ®Google Scholar
• HEY J, DEL PRADO M, SHERWOOD J, KRUETNER W, EGAN RW: Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model torsade de pointes. Armeimittelforschung (1996) 46:159–163.
   PubMed Web of Science ®Google Scholar
• CARMELIET E: Effects of cetirizine on the delayed K+ currents in cardiac cells: Comparison with terfenadine. Br J. Pharmacol (1998) 124:663–668.
   PubMed Web of Science ®Google Scholar
• SALE ME, BARBEY JT, WOOSLEY RL et al.: The electrocardiographic effects of cetirizine in normal subjects. Clin. Pharmacol Ther. (1994) 56:295–301.
   PubMed Web of Science ®Google Scholar
• RIDOUT SM, TARIQ SM: Cetirizine overdose in a young child. J. Allergy Clin Immunel (1997) 99:860–861.
   PubMed Web of Science ®Google Scholar
• DELGADO LF, PFERFERMAN A, SOLE D, NASPITZ CK: Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann. Allergy Asthma Immunol. (1998) 80:333–337.
   PubMed Web of Science ®Google Scholar
• LIDQUIST M, EDWARDS IR: Risk of non-sedating antihistamines. Lancet (1997) 349:1322.
   Web of Science ®Google Scholar
• SANGUINETTI MC, JURKIEWICZ NK: Two components of cardiac delayed rectifier K+ current: differential sensitivity to block by class III antiarrhythmic agents. j Gen. Physiol. (1990) 96:835–863.
   PubMedGoogle Scholar
• SALATA JJ, JURKIEWICZ NK, WALLACE AA, STUPIENSKI RF III, GUINOSSO PJ, LYNCH JJ JR: Cardiac electrophysiological actions of the histamine Hl-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ. Res. (1995) 76(1):110–119.
   PubMed Web of Science ®Google Scholar
• WARMKE JW, GANETZKY B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc. Natl. Acad. Li. USA (1994) 91:3438–3442.
   PubMed Web of Science ®Google Scholar
• SANGUINETTI MC, JIANG C, CURRAN ME, KEATING MT: A mechanistic link between an inherited and acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 81:299–307.
   PubMed Web of Science ®Google Scholar
• ROY M-L, DUMANIE R, BROWN AM: HERG: A primary human ventricular target of the non-sedating antihistamine terfenadine. Circulation (1996) 94:817–823.
   PubMed Web of Science ®Google Scholar
• SUESSBRICH H, WALDEGGER S, LANG, F, BUSCH AE: Blockade of HERG channels expressed in Xerropus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. (1996) 385:77–80.
   PubMed Web of Science ®Google Scholar
• BIANCHI L, WIBLE B, ARCANGELI A et al.: HERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. (1998) 58:815–822.
   Google Scholar
• TAGLIALATELA M, PANNACCIONE A, CASTALDO P et al.: The molecular basis for the lack of HERG KE channels block-related cardiotoxicity by the H1 receptor blocker cetirizine as compared to other second-generation antihistamines. Mol. Pharmacol. (1998) 54:113–121.
   PubMed Web of Science ®Google Scholar
• ••An important molecular-based studydemonstrating that cardiotoxicity by antihistamines via blockade of K± channels is not a property common to all second generation drugs.
   Google Scholar
• DEPLON E, VALENZUELA C, GAY P, FRANQUEZA L, SNYDERS DJ, TAMARGO J: Block of human cardiac Kv1.5 channel by loratadine: voltage-, time-, and use-dependent block at concentrations above therapeutic levels. Cardiovasc. Res. (1997) 35:341–350.
   Google Scholar
• TAGLIALATELA M, PANNACCIONE A, CASTALDO P, GIORGIO G, ANNUNZIATO L: Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br. Pharmacol. (2000) 131:1081–1088.
   PubMed Web of Science ®Google Scholar
• VAN CAUWENBERGE P, BACHERT C, PASSALACQUA G, BOUSQUET J, CANONICA GW, DURHAM SR: Consensus statement on the treatment of allergic rhinitis. Allergy (2000) 55:119–134.
   Google Scholar
• GEHA RS, MELTZER EO: Desloratadine: a new nonsedating oral antihistamine. Allergy OM. Immunol. (2001) 107:751–762.
   PubMed Web of Science ®Google Scholar
• •A very nice review comparing desloratadine with the parent compound loratadine.
   Google Scholar
• KREUTNER W, HEY JA, ANTHES J, BARNETT A, YOUNG S, TOZZI S: Preclinical pharmacology of desloratadine, a selective and non-sedating histamine H1 receptor antagonist: 1st communication: receptor selectivity, antihistaminic activity and antiallergic effects. Armeimittelforschung (2000) 50:345–342.
   PubMed Web of Science ®Google Scholar
• AGRAWAL DK: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig. Drugs (2001) 10:547–560.
   PubMed Web of Science ®Google Scholar
• •A very good overview of the anti-allergic and anti-inflammatory effects of desloratadine.
   Google Scholar
• MCCELLAN K, JARVIS B: Desloratadine. Drugs (2001) 61:789–796.
   PubMed Web of Science ®Google Scholar
• BAENA-CAGNANI CE: Desloratadine activity in concurrent seasonal seasonal allergic rhinitis and asthma. Allergy (2001) 56\(Suppl. 65):21–27.
   Google Scholar
• NAYAK AS, SCHENKEL E: Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy (2001) 56:1077–1080.
   PubMed Web of Science ®Google Scholar
• •This study shows that desloratadine can relieve nasal congestion in allergic rhinitis.
   Google Scholar
• Data on file, Schering-Plough, Kenilworth, NJ, USA.
   Google Scholar
• GUPTA S, BANFIELD C, KANTESARIA B et al.: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel group study. OM. Ther. (2001) 23:451–466.
   Google Scholar
• SCHARF MB, KAY GC, RIKKEN G, DANZIG MR, STAUDINGER H: Desloratadine has no effect on wakefulness or psychomotor performance. Allergy (2000) 55\(Suppl. 63). Abstract 280.
   Google Scholar
• VUURMAN E, RAMAEKERS JG, RIKKEN G, DE HALLEUX F: Desloratadine does not impair actual driving performance: a three way crossover comparison with diphenhydramine and placebo. Allergy (2000) 55\(Suppl. 63). Abstract 263.
   Google Scholar
• VALK PJL, VAN ROON DB, SIMONS M, RIKKEN G, LETHER IC, STAUDINGER H: No impairment of flying ability with desloratadine use in healthy volunteers under conditions of simulated cabin pressure. Allergy (2001) 56\(Suppl. 68). Abstract 229.
   Google Scholar
• MARKHAM A, WAGSTAFF AJ: Fexofenadine. Dugs (1998) 55:269–274.
   Google Scholar
• SYMPSON K, JARVIS B: Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Dugs (2000) 59:301–321.
   Google Scholar
• •Comprehensive review on fexofenadine.
   Google Scholar
• CIPRANDI G, COSENTINO C, MILANESE M, MONDINO C, CANONICA GW: Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy (2001) 56:1068–1070.
   PubMed Web of Science ®Google Scholar
• •This study demonstrates the positive effects of fexofenadine on nasal blockade in allergic rhinitis.
   Google Scholar
• BOWER E, MOORE J, MOSS M, SELBY K, AUSTIN M, MEEVES S: Effects of single dose fexofenadine, diphenhydramine, and placebo on cognitive and psychomotor performance in naval flight personnel in a double blind, crossover randomised study. Allergy (2000) 55\(Suppl. 63):912.
   Google Scholar
• HINDMARCH I, SHAMSI Z, STANLEY N, FAIRWEATHER DB: A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br. j Clin. Pharmacol. (1999) 48(2)200–206.
   Google Scholar
• NICHOLSON AN, STONE BM, TURNER C, MILLS SL: Antihistamines and aircrew: usefulness of fexofenadine. Aviat. Space Environ. Med. (2000) 71:2–6.
   PubMed Web of Science ®Google Scholar
• HINDMARCH I, SHAMSI Z, KIMBER S: An evaluation of the effects of high dose fexofenadine on the rental nervous system: a
   Google Scholar
• •• double-blind, placebo controlled study in healthy volunteers. Clin. Exp. Allergy (2002) 32:133–139.
   Google Scholar
• •A well-performed study on the CNS effects of high doses of fexofenadine given to healthy volunteers.
   Google Scholar
• VERMEEREN A, O'HANLON JF: Fexofenadine's effects, alone and in combination with alcohol, on actual car driving and psychomotor performance. Allergy Clin. Immurrol. (1998) 101:306–311.
   PubMed Web of Science ®Google Scholar
• WEILER JM, BLOOMFIELD JR, WOODWORTH GG et al.: Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomised, placebo-controlled trial in the Iowa driving simulator. Ann. Intern. Med. (2000) 132(5):354–363.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN DI, SCHOENWETTER WF, NATHAN RA et al.: Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann. Allergy Asthma konurrol. (1997) 79:443–448.
   PubMed Web of Science ®Google Scholar
• BRONSKY EA, FALLIERS CJ, KAISER HB et al.: Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist in the treatment of fall allergies. Allergy Asthma Proc. (1998) 19:135–141.
   PubMed Web of Science ®Google Scholar
• GRAFT DE BERNSTEIN DI, GOLDSOBEL A, MELTZER EO, PORTNOY J, LONG J: Safety of fexofenadine in children treated for seasonal allergic rhinitis. Ann. Allergy Asthma bronurrol. (2001) 87:22–26.
   PubMed Web of Science ®Google Scholar
• •Demonstrates fexofenadine to be safe and efficacious in children with seasonal allergic rhinitis.
   Google Scholar
• ANONYMOUS: Severe cardiac arrhythmia on fexofenadine?Prescrire Int. (2000) 9:212.
   Google Scholar
• PINTO YM, VAN GELDER IC, HEERINGA M, CRIJNS HJGM: QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet (1999) 353:980.
   PubMed Web of Science ®Google Scholar
• GILLARD M, VAN DER PERREN C, MOGUILEVSKY N et al.: Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194) Mal Pharmacol. (2002) 61:391–399.
   Google Scholar
• DEVALIA JL, DE VOS C, HANOTTE F, BALTES E: A randomised double-blind crossover comparison among cetirizine, levocetirizine and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy (2001) 56:50–57.
   PubMed Web of Science ®Google Scholar
• GRANT JS, RIETHUISEN JM, MOULAERT B, DEVOS C: A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebasine, fexofenadine, loratadine, mizolastine and placebo: suppression of histamine-induced wheal and flare response during 24 hours in healthy male subjects. Ann. Allergy Asthma konurrol (2002) 88:190–197.
   PubMed Web of Science ®Google Scholar
• CLOUGH GE BOUTSIOUKI E CHURCH MK: Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy (2001) 56:985–988.
   PubMed Web of Science ®Google Scholar
• WANG DY, HANOTTE F, DE VOS C, CLEMENT P: Effect of cetirizne, levocetirizine and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy (2001) 56:339–343.
   PubMed Web of Science ®Google Scholar
• •Comprehesive study comparing levocetirizine with the parent compound cetirizine for their effects on histamine-induced nasal response.
   Google Scholar
• LEYNADIER F, MEES K, ARENDT C, PINELLI ME: Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhirrolaryngol Belg. (2001) 55:305–312.
   PubMedGoogle Scholar
• THOMSON L, BLAYLOCK MG, SEXTON DW, CAMPBELL A, WALSH GM: Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin. Exp. Allergy (2002)32:1187–1192.
   PubMed Web of Science ®Google Scholar
• HINDMARCH I, JOHNSON S, MEADOWS R, KIRKPATRICK T, SHAMSI Z: The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance and weal and flare. Cum: Med. Res. Opin. (2001) 17:241–255.
   PubMed Web of Science ®Google Scholar
• •Comprehensive and well-controlled study showing that levocetirizine, cetirizine and loratadine have no significant disruptive and sedative effects on objective measurements of cognitive function and psychomotor performance.
   Google Scholar
• ETAC STUDY GROUP: Allergic factors associated with the development of asthma and the influence of cetirizine on this progression in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Ped. Allergyhmnuriol. (1998) 9:116–124.
   PubMed Web of Science ®Google Scholar
• ••Fascinating study, which provides evidencethat cetirizine may be able to halt the progression to asthma in high-risk groups of young children and infants.
   Google Scholar
• HOLGATE ST: Considerations on third generation antihistamines. Clin. Exp. Allergy (2002) 32:179.
   PubMed Web of Science ®Google Scholar